CPT code 81479 designates an unlisted molecular pathology procedure and is used when a molecular or genomic test lacks a specific CPT code. Nationally, this code matters because it captures novel, customized, or otherwise uncoded molecular diagnostic assays that are increasingly used for precision medicine, rare disease evaluation, and complex oncology testing. Payers apply differing policies for coverage and reimbursement of unlisted molecular tests, making coding clarity and documentation critical for claims processing.

Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an explanation of what 81479 represents, the clinical and laboratory contexts in which it is used, and where it typically appears on claims. The publication outlines typical payer considerations, claims documentation expectations, and the kinds of benchmarks and policy updates that affect use of unlisted molecular pathology codes.

This summary equips billing managers, laboratory directors, and policy analysts with a concise orientation to 81479, what stakeholders review when processing unlisted molecular tests, and the areas where payers commonly exercise medical necessity, prior authorization, and clinical evidence review. Data not available in the input for specific payer policies, associated taxonomies, ICD-10 pairings, and detailed reimbursement benchmarks.